$ETNB News

Last published 1y ago

1y agoETNB RHHBYRoche purchases shares in tender offer for 89bio, IncGlobeNewswireBasel, 30 October 2025 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered and not validly
1y agoETNB RHHBYRoche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cashGlobeNewswireBasel, 1 October 2025 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ:ETNB) at a price of $14.50
1y agoETNB89bio, Inc. Announces Agreement to be Acquired by RocheGlobeNewswire– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash;
1y agoETNB RHHBYRoche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASHGlobeNewswire89bio's pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition
1y agoETNB89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)Earnings Call Transcripts
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative
1y agoETNB89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
1y agoETNB89bio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
1y agoETNB89bio Reports Second Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswire– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio Reports First Quarter 2025 Financial Results and Corporate UpdatesGlobeNewswire– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with
1y agoETNB89bio to Participate in the Leerink Partners Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative
1y agoETNB89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesGlobeNewswire– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
1y agoETNB89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
1y agoETNB89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
1y agoETNB89bio Provides Business Update and Outlook for 2025GlobeNewswire– Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in patients with
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
1y agoETNB89bio to Participate in the 7th Annual Evercore HealthCONx ConferenceGlobeNewswireSAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative
1y agoETNB89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024GlobeNewswireSAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of
1y agoETNB89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
1y agoETNB89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the
2y agoETNB89bio Reports Third Quarter 2024 Financial Results and Corporate UpdatesGlobeNewswire– The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Topline
2y agoETNB89bio to Participate in the UBS Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024GlobeNewswireSAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor ConferenceGlobeNewswireSAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative
2y agoETNB89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerGlobeNewswireSAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of
2y agoETNB NBTXNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term GrowthGlobeNewswireDr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boardsMs. Anat Naschitz, proven life science investor and
2y agoETNB89bio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio Appoints Francis Sarena as Chief Operating OfficerGlobeNewswireSAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Reports Second Quarter 2024 Financial Results and Corporate UpdatesGlobeNewswire–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are
2y agoETNB89bio Appoints Charles McWherter, Ph.D., to its Board of DirectorsGlobeNewswireSAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, July 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver CongressGlobeNewswireSAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisGlobeNewswire—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve
2y agoETNB89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
2y agoETNB89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this quarter in MASH
2y agoETNB89bio to Participate in the BofA Securities 2024 Health Care ConferenceGlobeNewswireSAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHGlobeNewswireSAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver
2y agoETNB89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsGlobeNewswireSAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of